Anaptys Bio

AnaptysBio is a clinical stage biotechnology company developing antibody product candidates. The company's programs, ANB020 and ANB019, neutralize therapeutic targets that are genetically related to inflammatory disorders in humans. ANB020 inhibits the activity of the interleukin-33 cytokine for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma. ANB019 inhibits the interleukin-36 receptor for the treatment of rare inflammatory diseases including generalized pustular psoriasis and palmo-plantar pustular psoriasis. The company's pipeline includes checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
  • TickerANAB
  • ISINUS0327241065
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for ANAB

ValuEngine Rating and Forecast Report for ANAB

ValuEngine Rating and Forecast Report for ANAB

ValuEngine Rating and Forecast Report for ANAB

David Nierengarten ...
  • Jeffrey La Rosa

1Q19 Financials; Multiple Data Readouts Expected in the Next Six Months

David Nierengarten ...
  • Jeffrey La Rosa

1Q19 Financials; Multiple Data Readouts Expected in the Next Six Months

ValuEngine Rating and Forecast Report for ANAB

ValuEngine Rating and Forecast Report for ANAB

ValuEngine Rating and Forecast Report for ANAB

ValuEngine Rating and Forecast Report for ANAB

ValuEngine Rating and Forecast Report for ANAB

ValuEngine Rating and Forecast Report for ANAB

ValuEngine Rating and Forecast Report for ANAB

ValuEngine Rating and Forecast Report for ANAB

ValuEngine Rating and Forecast Report for ANAB

ValuEngine Rating and Forecast Report for ANAB

ResearchPool Subscriptions

Get the most out of your insights

Get in touch